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As populations expand and age, increasing demands are made 
on health resources. Policy makers are required to set priorities 
and engage in trade-offs to ensure that every dollar, rupee, and 
rand is spent wisely to maximise value1. This is true for high and 
low income countries alike, where resources are finite, and all 
demands upon those finite resources cannot be met. However, 
in low and middle income countries (LMIC), where some of the 
largest populations reside, and resources are particularly scarce, 
making the right trade-offs is arguably of greater importance, 
where the opportunity cost of making the wrong decision can be a 
matter of life and death1–3.
Health Technology Assessment (HTA) provides a globally-
accepted and structured approach to synthesising evidence for cost 
and clinical effectiveness alongside ethical and equity considera-
tions to inform evidence-based priorities1,4. Almost all high income 
countries across the world use HTA as a means to systematically 
consider evidence for clinical and cost effectiveness of new tech-
nologies to inform health spending decisions5. Increasingly, systems 
for generating and utilizing HTA evidence to improve allocative 
efficiency are also being used in upper middle income countries, 
such as Thailand6,7, and South Africa8. Indeed, the use of HTA is 
credited as one of the key contributors to Thailand’s successful 
Universal Health Coverage (UHC) program, where the Health 
Intervention Technology Assessment Program (HITAP) routinely 
conducts HTA as part of the decision-making process for inclu-
sions and exclusions into the country’s UHC Scheme, and National 
List of Essential Medicines7,9,10. The World Health Organisation 
signed a health intervention technology assessment resolution in 
2014 to support the importance of HTA as an essential compo-
nent of achieving Universal Health Coverage4,11, elevating the 
global recognition of HTA as an important lever for health system 
reform.
India is one of the most recent countries to formally commit to 
institutionalising HTA as an integral component of the heath 
resource allocation decision-making process. This has been rec-
ognised in official government policy, including the 12th Five Year 
Plan12, the Niti Aayog 3 year Action Plan13, and the recently 
released National Health Policy14, marking an important shift in the 
government’s commitment toward more effective resource alloca-
tion for health. The government is in the process of establishing a 
national HTA body within the Department of Health Research 
(DHR), a medical research department within the Ministry of 
Health and Family Welfare, which will use HTA as a means 
to evaluate the cost effectiveness of new and existing health 
technologies to support resource allocation decisions at both the 
central and state levels15.
The effective conduct of HTA depends on the availability of reli-
able data sources to enable the comparative assessment of the 
clinical and cost effectiveness of a given intervention within the 
Indian healthcare context16,17. Locally-generated data is essen-
tial to provide context-specific inputs into a HTA, and the 
absence of such data poses a serious challenge in building accu-
rate economic models that are statistically robust and truly repre-
sentative of the context in which they were designed to model and 
inform. There is a marked absence of strong health information 
systems in LMIC, and this poses a significant bottleneck to the 
efficient generation and deployment of HTA into the health deci-
sion space4,18. India is no exception in this respect, where there 
is limited availability of high-quality clinical, cost, equity, and 
health related quality of life studies conducted in the country. 
Overcoming these data challenges will present a significant hurdle 
in India’s journey towards institutionalising HTA and effectively 
embedding economic analysis into the priority setting process.
In this paper, we aim to document the currently available local data 
to meet the needs of undertaking economic analysis in India. We 
will outline each of the necessary data components required for 
the conduct of HTA, the availability of such data in India, where 
data can be accessed, and the different ways in which researchers 
can overcome the challenges of missing or low quality data. We 
note that many additional components within the complex HTA 
ecosystem are of equal importance, including human resources 
with technical capacity to undertake analyses, and strong politi-
cal commitment to use HTA evidence to inform policymaking, 
however we will focus here on data requirements only.
Methods
The information presented here is drawn from the experience 
of the authors in conducting and contributing to health economic 
analyses, including HTA, in the Indian context. We first identi-
fied the key areas of information needed for these types of analy-
ses (see Figure 1). We then used our own experience to document 
data sources in each of these areas. The authors also approached 
key informants working within the broad field of evidence science 
in India for additional inputs and to ensure that the information 
presented here was sufficiently comprehensive. Finally, each 
source of data was assessed for its ability to fulfil the needs of HTA. 
Although, this is not intended to provide an exhaustive account 
of all databases available across India, this should offer a starting 
point for researchers wishing to engage in HTA using data from 
India.
Results
Data needs
To construct an economic model for HTA that includes both the 
costs and impact of a health care programme or intervention 
within a particular context, data in a range of key areas is needed. 
      Amendments from Version 1
We have made minor amendments to the paper in order to 
address the reviewer’s comments. These changes include: The 
addition of text regarding vertical program data from government-
sponsored schemes under the ‘service use/consumption’ section; 
the restructuring of the costing section into patient expenditure 
and service provision to make the distinction between these 
two areas of costing data clearer; the addition of text to the 
description of the costing database study to clarify that no 
other single database of this kind exists in India, to the best of 
the authors knowledge; the amendment of the conclusion to 
more clearly summarise the key findings of the paper and their 
significance to the institutionalization of HTA in India.
See referee reports
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We have grouped data needs from these areas into the following 
categories: clinical efficacy; cost; epidemiology; quality of life; 
service use/consumption; and equity.
Information on clinical efficacy is necessary in order to 
understand whether a given intervention is doing what it was 
intended to do, and how well it achieves this, compared to all 
reasonable comparators. This is primarily established through 
randomised controlled trials (RCTs).
In the area of costs, data is needed on the cost of providing a serv-
ice, or set of services, to providers and patients in order to conduct 
a comprehensive economic evaluation to determine cost effective-
ness. Cost data is outlined in this paper from a health provider 
and healthcare perspective16,19, as recommended by the reference 
case for economic evaluation by the international decision support 
initiative (iDSI;20). This covers the direct patient and family costs 
related to the purchase of healthcare, as well as the costs borne by 
healthcare providers.
Country-specific epidemiological data is what allows researchers 
to contextualise an economic model and ensure that any conclu-
sions drawn from the results of the model are appropriate for 
that given context. Epidemiological information includes demo-
graphics, vital statistics and burden of disease data. Demographics 
refers to quantifiable characteristics of a given population, such 
as gender, geographic location, or socio-economic income 
status. Vital statistics are information relating to births and deaths 
of a population, including age at death and the cause. Burden of 
disease refers to the impact of a health problem on a population, 
and can be measured by financial cost, mortality, morbidity, or 
other indicators such as quality adjusted life years (QALYs) or 
disability adjusted life years (DALYs). Together, this data underpins 
a large part of what constitutes an economic evaluation model.
Service use data provides information regarding how many peo-
ple are using a particular service or seeking care which requires a 
certain intervention. This estimated uptake data is used alongside 
epidemiological data regarding disease prevalence in economic 
models to estimate the population impacted by an intervention 
or service. It is also used in estimating the costs of a particular 
intervention or health care activity and to inform estimates of the 
likely budget impact of introducing a new intervention into the 
health system.
Health Related quality of life data is used to calculate how a given 
intervention affects quality of life (QoL), and calculate associated 
quality adjusted life years (QALYs). QALYs are a metric used to 
estimate an incremental cost effectiveness ratio (ICER), and are 
the most commonly used metric to represent the impact a therapy 
has on the length of life while also taking into account any changes 
in the health-related QoL. QoL datasets are comprised of two sepa-
rable components – a comprehensive set of health state information 
based on stated preferences to each QoL dimension, and a weighted 
utility value generated for that given health state21. The latter 
component is used to calculate QALYs. It is also possible to uti-
lise burden of disease data, in the form of disability adjusted life 
years (DALYs), as an alternative to the QALY to capture the 
disability associated with living with a given condition, and the 
alleviation of disability after an intervention, in an economic 
analysis.
Data regarding equitable and equal access, and utilisation of serv-
ices is essential to allow for ethical information to be considered 
in the decision-making process alongside evidence of cost effec-
tiveness. In the Indian context, this may relate to inequity as a 
consequence of gender, caste, religious beliefs, age, geographic 
location, socio-economic status22–24.
Further information for each data source is provided below, 
and summarised in Table 1.
Data quality
No formal data quality assessment was carried out by the present 
authors. However, the Niti Aayog, in collaboration with the 
Ministry of Health and Family Welfare and the World Bank, have 
recently published a comprehensive India health index report25, 
which draws from many of the same data sources outlined below, 
including the National Family Health Survey and the Health 
Management Information System portal data, where a thorough 
quality assessment was undertaken. The authors cite poor data 
quality as a major limitation of their health index estimates, high-
lighting a need for urgent improvement in the capture of health 
and demographic data and the adoption of robust data quality 
mechanisms across India. As such, all researchers undertaking 
Figure 1. Data requirements for HTA, and key questions that 
each data component contributes to answering as part of a 
given economic analyses. Key: QOL = quality of life; Epidem. = 
epidemiology.
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Table 1. Summary of key National data sources relevant to the conduct of HTA in India.
HTA-related information Data Source Commissioning 
body
Data Collection method Equity-relevant 
information
Website
Epidemiology 
(communicable disease)
Integrated 
disease 
surveillance 
program
MHFW Reporting by health and 
medical officers
Geographic location http://idsp.nic.in/
Epidemiology, Service use, 
health expenditure
Health 
Management 
Information 
System
MHFW Reporting by facility-level 
data manager
Gender, Geographic 
location,
https://nrhm-mis.nic.in/SitePages/Home.aspx
Epidemiology, Service 
Use, OOP spending (for 
institutional delivery only)
National 
Family Health 
Survey (NFHS) 
2015/2016,
MHFW Survey Agency staff 
trained by IIPS to 
undertake field work
Location, gender, 
ethnicity, age, marital 
status, contraception 
use, HIV status, health 
insurance, water/
sanitation access, 
literacy, female parity
https://dhsprogram.com/data/dataset/India_Standard-
DHS_2015.cfm?flag=1
Epidemiology Sample 
Registration 
System (SRS) 
Census (2011)
MHA Household census data 
collected by trained 
census officers
Location, gender, 
religion, education, 
occupation, caste/tribe, 
language, socio-
economic status
http://censusindia.gov.in/Vital_Statistics/SRS/Sample_
Registration_System.aspx
Health and service 
use/utilization for RMNCH 
indicators
District Level 
Household 
Survey 
(2011/2012)
MHFW Regional Agency 
staff trained by IIPS to 
undertake field work
Accessibility of services 
to women and children 
in rural villages
http://rchiips.org/
Epidemiology, service use, 
OOP spending (‘Indicators 
of social consumption: 
NSSO 2014’)
National 
Sample Survey 
Office Census 
(NSSO; 2014)
MS Data officers for 6 Zonal 
Offices, 49 Regional 
Offices and 118 Sub-
Regional Offices collect 
primary data
Location, Socio 
economic status, 
Gender, Rural/urban, 
Age
http://mospi.nic.in/national-sample-survey-office-nsso
Safety, efficacy, clinical 
comparator(s)
ICMR Clinical 
Trials Registry
ICMR Any medical researcher 
involved in the conduct of 
a clinical trial
No http://ctri.nic.in/Clinicaltrials/advancesearchmain.php
Epidemiology - Cancer ICMR Cancer 
Registry 
Program
ICMR 31 population-based 
and 29 hospital-based 
registries
Location, gender, Rural/
urban, Age
http://ncdirindia.org/cancersamiksha/
Health expenditure National heath 
Accounts 
(2014/2015)
MHFW Secondary data 
synthesized from many 
primary sources, full list 
detailed in document
Public and private sector 
expenditure
https://mohfw.gov.in/sites/default/files/8949831122147
1416058.pdf
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HTA-related information Data Source Commissioning 
body
Data Collection method Equity-relevant 
information
Website
Billing/Price Database 
of Indian 
Health Benefit 
Packages
WHO India 
Country Office
Database listing service 
packages and rates 
across 22 GFHIS
No https://public.tableau.com/profile/who.insurance.ben.
pack#!/vizhome/BenPackBoxPlot_0/Dashboard2
Billing/Price Central 
Government 
Insurance 
Scheme Rates 
information
CGHS List of reimbursement 
rates for all procedures 
covered under CGHS
No http://msotransparent.nic.in/writereaddata/cghsdata/
mainlinkfile/File811.pdf
Billing/Price RSBY package 
reimbursement 
rates
RSBY List of reimbursement 
rates for all procedures 
covered under RSBY
No http://www.rsby.gov.in/Documents.aspx?id=4
Equity Socio-economic 
and Caste 
Census (2011)
MRD Data collected by 
Government servant 
enumerators, entered 
by Central Public Sector 
Enterprise officer
Socio economic status, 
caste, religion, living 
conditions, source of 
income
http://secc.gov.in/welcome
Epidemiology, Equity Health States, 
Progressive 
India – Health 
Index report
Niti Aayog State rankings by index 
measure derived from 
various sources
Geography, gender, sex 
ratio, poverty
http://social.niti.gov.in/hlt-ranking
Table 1 key: GFHS, Government Financed Health Insurance Schemes; HTA, Health Technology Assessment; ICMR, Indian Council of Medical Research; MHFW; Ministry of health and family welfare; MRD, 
ministry of rural development; MS, ministry of statistics;; MHA, Ministry of Home Affairs; OOP, out of pocket spending; SRS, sample registration system; WHO, World Health Organisation.
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economic analyses in India should interpret secondary data with 
caution, and triangulate multiple sources where possible to better 
understand the data reliability.
Clinical efficacy and safety
Robust HTA depends on reproducible and verifiable insights into 
the clinical effectiveness of a given health intervention17,19. Indeed, 
it is impossible to establish whether a technology is cost effec-
tive if clinical efficacy is unknown or ill-established. Clinical 
efficacy data is generally available in the published literature for 
interventions that are presently available in the market. Large RCTs 
are the optimal source of clinical efficacy data, and these should 
inform clinical outcome estimates wherever possible. System-
atic reviews and Meta analyses of RCTs are the gold standard for 
deriving clinical outcome and safety metrics. In the case of novel 
technologies, outcome data may be provided by manufacturers 
and industry and should be interpreted with caution. The Central 
Drugs Standard Control Organization (CDSCO) is the National 
Regulatory Authority in India and publishes a list of approved 
pharmacological interventions and their indications in India, which 
is updated regularly. All clinical trials in India are registered in 
the Clinical Trials Registry of India (CTRI), which is a primary 
register connected to the International Clinical Trials Registry 
Platform (ICTRP), an international registry run by the World 
Health Organization, which houses global data on clinical 
trials26. The Indian Council of Medical Research (ICMR) is the 
apex body responsible for the formulation, coordination and 
promotion of all biomedical research in India, and is a signatory 
to the WHO joint statement on clinical trials, which mandates that 
all clinical trials that they fund, co-fund or support would provide 
public disclosure of results within a year of trial completion27.
The Cochrane Library is the largest international repository of 
systematic reviews and meta-analyses and should be searched as 
a first port of call for any pooled statistics regarding clinical effi-
cacy. The ICMR has established an Advanced Centre for evidence-
based medicine that hosts the South Asian Cochrane Network and 
Centre at the Christian Medical College, Vellore, and has pro-
cured a national subscription to The Cochrane Library to ensure 
that it is accessible to scientists across India28. Researchers should 
conduct a thorough quality appraisal for all evidence used in an 
economic analyses, using checklists such as CASP or GRADE. 
The Cochrane Collaboration provides a useful pathway and 
tutorial for analysts to use to guide approaching grading the 
quality of evidence. Quality of the data inputs should be trans-
parently reported and taken into consideration when using the 
evidence from the evaluation to inform decision making.
There may be circumstances where clinical efficacy data should 
be locally sourced, such as for certain technical surgical interven-
tions, diagnostics that require skilled interpretation, and public 
health programs that are highly context-specific. Outcomes of 
these interventions may vary based on training and knowledge of 
practitioners, and availability of adequate infrastructure and equip-
ment. Researchers should seek expert clinical advice regarding 
sources of data and appropriateness of transferring international 
data for use in economic evaluations to inform decision making 
in India.
Epidemiological data
Demographics
The government of India collects epidemiological information 
periodically through the Health Management Information System 
(HMIS) and other varied survey sources such as National Family 
Health Survey (NFHS), District Level Household Survey (DLHS; 
for reproductive and child health information), and Sample 
Registration System (SRS) census data. The Most recent round 
of the NFHS, also known as the District House Survey, data 
(2015–2016) is the most comprehensive source of primary 
demographic data in India, where information was collected 
from over 600,000 households. The Niti Aayog, in collabora-
tion with the Ministry of Health and Family Welfare and the 
World Bank, have recently published a comprehensive India 
health index report25, which draws on each of the aforemen-
tioned data sources to compile a set of health index statistics 
for each state and union territory across India. This report high-
lights key information such as neonatal mortality rate, under-five 
mortality rate, full immunization coverage, institutional deliv-
eries, and rates of both communicable (TB and HIV) and non- 
communicable diseases across each State and Union territory.
Burden of disease
Burden of disease refers to the impact of a health problem on a 
given population. An important new source of disease burden 
data for India has recently been published by the Indian Council 
of Medical Research (ICMR) and the Public health Foundation 
of India (PHFI), in collaboration with the Institute for Health 
Metrics and Evaluation (IHME29). This study collected, collated, 
and synthesized census information, vital registration statistics, 
Sample Registration System information, large scale national 
household surveys, cohort studies, disease surveillance data, 
disease-programme-level data, and administrative records of 
health services and disease registries in order to estimate disease 
burden in every state and union territory of India. This marks 
an important step forward in terms of data availability at the 
state-level for burden of disease and will provide an invaluable 
resource for researchers undertaking economic analyses in India.
Further disease-specific epidemiological data is generally avail-
able for most conditions in the published literature, though avail-
ability varies according to condition. Much of the epidemiological 
data regarding infectious and communicable disease in India 
is captured by the integrated disease surveillance program, a 
Ministry of health and family welfare department under the 
directorate general of health services. There are also a number of 
condition-specific programs within the Ministry of Health and 
family welfare which collect condition-specific information, such 
as the National program for the control of blindness, or National 
Programme for Prevention and Control of Cancer, Diabetes, 
Cardiovascular diseases and Stroke (NPCDCS). The ICMR 
also runs a network of 26 disease specific institutes across India, 
such as the Antimicrobial Resistance Surveillance Network, or 
the Rotavirus Surveillance Network, which collate data on 
clinical, epidemiological, and virological information, which is 
used to devise evidence-based treatment guidelines to improve care 
and monitor and evaluate transmission-modifying interventions 
such as vaccines. Researchers conducting a HTA study in India 
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should consult the  Ministry of Health and Family Welfare 
website, and individual ICMR institute websites (e.g. National 
institute of Research in Tuberculosis or National Institute of 
Malaria Research – see the ICMR website for a full list of insti-
tutes) to check whether additional epidemiological information is 
available for their clinical area of interest.
Vital statistics (mortality)
The Sample Registration System, part of the government census 
program, is mandated to collect verbal autopsy data in India. 
However, the completeness and quality of vital registration data 
for mortality in India has been highlighted as inadequate, where 
a recent assessment of the national civil registration and vital 
statistics systems in place found that available data was incom-
plete and of poor quality, with a medically-certified cause of death 
certificate recorded in only ~16% of the total death registered30. In 
order to address this paucity of reliable data, the ICMR will build 
on its previous efforts to capture cause of death in 200931, and 
undertake a thorough verbal autopsy study in early 2018. The 
global collaborative Million Deaths Study, which has been 
commissioned by the Registrar General of India since 2001, 
has also collected data in 1.3 million homes in more than 
7000 randomly selected areas of India, and provides a useful 
resource for estimation of mortality data in India32,33.
Cost
Cost information is a key component for the process of HTA 
to inform both cost-effectiveness analysis and budget impact 
analysis. Cost data is not consistently available across each state 
and level of the health system in India. Primary research has been 
undertaken in isolated instances to capture costs for a specific 
condition or level of care within a given district, however such 
data is limited.
Healthcare costs: patient expenditure
High healthcare costs combined with low social health insurance 
penetration has resulted in high out-of-pocket (OOP) expenditure 
for people across the country, where OOP spending makes up over 
80% of health spending in India and represents a major contributor 
to financial impoverishment29,30. OOP spending therefore represent 
a critical component of the costs of health care delivery in India. 
Additional costs such as costs to other sectors and wages forgone 
are not covered in this paper. Data for OOP spending was col-
lected as part of the most recent National Sample Survey Office 
(NSSO; 2014), under the ministry of statistics. Cost data captured 
by the NSSO relates to expenditure on medicine; reluctance to seek 
medical services due to financial constraints; reliance on 
borrowings for medical expenditure; coverage by a health insur-
ance program; expenditure on institutional childbirth; expenditure 
on hospitalisations and non-hospitalised treatment. In the NSSO 
survey, OOP can be broken down by broad health condition but 
are not disease specific. A number of primary research studies 
have also been published which provide additional data on OOP at 
the district level across numerous states, and these can be used to 
complement NSSO.
Healthcare costs: service delivery
Service delivery data covers cost of all activities related to the 
provision of healthcare; including medical and allied health 
professional staff costs, and unit costs of equipment and infra-
structure utilised during the delivery of care. Cost data is generally 
unavailable for service and unit indices, and primary data 
collection is required in most instances in order to obtain this 
information.
The World Health Organisation India country office has recently 
undertaken a comprehensive exercise to collate information on 
the packages of services covered by 22 different Government 
funded Health Insurance Schemes across the country, and their 
service rates. This is the first exercise of its kind to bring together 
information form myriad schemes across the country into a single 
database. This information can be used to compare coverage of 
services across different packages, and the rates at which those 
services are delivered. This database provides both package 
rates averaged across schemes by state and disaggregated by 
individual packages. This provides a highly useful starting point 
for any researcher undertaking a cost effectiveness analysis in 
understanding coverage and price of specific services, provid-
ing that those services are covered by any government funded 
scheme. However, it must be noted that these estimates are 
reflective of tendering price and thus cannot be assumed as 
accurate reflections of true cost.
Insurance claims data also provide an important source of 
information on the cost of health care in India. Insurance claims 
databases contain rich data on secondary care (hospital) claims 
for individual procedures, however, this data is not routinely made 
publicly available and reflects the tendered price of healthcare, 
rather than the actual cost of procuring and providing a given 
service. There are isolated databases of such information, such as 
reimbursement rates for the Central Government Health Scheme, 
or rates of services covered under RSBY. Should this kind of data 
be made more widely available for public access and scrutiny in 
future, it would provide an insight into the financing of healthcare 
in both the public and private sectors, which could help inform 
more reliable economic models.
There is no single repository for all cost data studies in India, and 
to date the major source of cost data for public sector has been 
individual cost studies. In light of the general paucity of cost 
data , particularly in relation to disease-specific cost information 
and disaggregated estimates for individual units costs in India, 
a large primary costing study has been undertaken by the Post 
Graduate Institute of Medical Education and Research  (PGIMER) 
in Chandigarh, Haryana, where provider cost data has been 
collected from a sample of over 200 health facilities across 
6 states, covering all levels of the health system (more informa-
tion is available online). Once finalised, this data will be made 
freely available in the form of an online database resource. The 
aim of this database is primarily to inform the HTA process, and 
all researchers across India will be able to use its contents to 
generate unit cost data to inform their analyses. 
At the global level, The WHO has also recognised the lack of 
reliable national cost data, and developed two tools to support 
national costing studies: WHO Cost effectiveness and Strategic 
Planning (WHO CHOICE) and the WHO OneHealth tool. The 
former provides country level estimates of unit costs for inpatient 
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and outpatient services for the public and private sectors, but is 
now largely outdated. The latter attempts to equip policymak-
ers and health service planners with a framework for informing 
scenario analysis, costing, health impact analysis, budgeting and 
financing of strategies for all major diseases and health system 
components. However, it requires local level data to inform these 
scenarios. At the diseases-specific level, the Global Health Cost 
Consortium (GHCC) provides an additional tool to improve 
resources to estimate the costs of TB and HIV programs through 
encouraging greater transparency and standardisation in costs 
data collection methods. The GHCC has also developed a unit 
costs study repository which provides a comprehensive database 
of a vast array of unit costs by country, including India, related to 
delivery of HIV and TB services.
Quality of life
Health Related quality of life data is used to calculate how a 
given intervention affects quality of life. The European Quality 
of life 5 dimensions (EQ5D) is the most commonly used generic 
QoL measure, and has become the cornerstone of HTA in many 
countries. No comprehensive national dataset for QoL has been 
collected for India, however, a small number of studies have col-
lected condition-specific EQ5D data34. Researchers undertak-
ing HTA in India who wish to generate QALYs will be required 
to collect condition-specific EQ5D data to inform their analyses. 
In the absence of a national QoL tariff for India, utility weights 
(necessary to calculate a QALY) will need to be transferred 
from an appropriate existing source, for example that of other 
countries in the region such as Thailand (see the EuroQol 
webpage for a list of all published country value sets). It is 
important to note that there are issues with transferring EQ5D 
datasets across countries, which can be explained by both 
methodological differences as well as socio-cultural differences 
between countries, and researchers should keep this in mind 
when using international tariffs to estimate local QoL data35.
At the global level, the Global Burden of Disease study (GBD) has 
collected world-wide data to calculate country-specific burden of 
disease estimates, including for the Indian population. Burden of 
disease can then be used to calculate DALYs, whereby one DALY 
equal the sum of number of years of life lost prematurely (YLLs) 
and a weighted measure of years lived with disability due to dis-
ease or injury (YLDs). YLL uses the life expectancy at the time of 
death, which can be obtained from the Sample Registration Sys-
tem Census database of vital statistics (2011). YLD is determined 
by the number of years disabled weighted by level of disability 
caused by a condition or disease, where the disability weights are 
derived from the GBD data. Many LMIC have taken to using GBD 
study estimates to inform economic analyses in the absence of 
locally-generated quality of life data. The limitations of such an 
approach should be noted, where the DALY does not easily allow 
for the modelling of different disease states, and the value judge-
ments used to weight DALY estimates are those of international, 
rather than local, experts.
Service use/consumption
Service use data is collected in 2 ways: Through census surveys and 
household questionnaires; and directly through service providers.
The National Family Health Survey (NFHS), and the National 
Sample Survey Office (NSSO) census surveys are the largest 
surveys in India, and collect individual responses regarding 
consumption of both health and non-health services across the 
country. Special attention was paid to the collection of health-
related information in the 2014 NSSO survey at the request 
of the Ministry of Health and Family Welfare, where the first 
national-level information was collected on rates of hospitalisa-
tion, medical care received as in-patient in medical institutions, 
the broad disease areas for which such medical care was sought, 
the extent of use of Government hospitals, and out of pocket 
expenditure on medicines and other health-related products 
incurred was also collected. Expenditure incurred on treatment 
received from public and private sectors was also accounted for.
While healthcare use data is typically collected by insurers, insur-
ance schemes do not routinely publish this data for public access. 
Several State-level insurance schemes do publish high-level claims 
data and report figures on service use, for example Aarogysari 
scheme in Telangana publishes their annual claims data online 
each year. Third Party Administrators process most insurance-
related claims in India, and hold data regarding institutional-level 
service use, however this data is also not easily available and 
not routinely released.
Data regarding uptake of services for particular conditions is also 
collected by government-sponsored vertical programs, such as the 
National Aids Control Organization (NACO), and the National 
Program for the Control of Tuberculosis. HTA researchers should 
consult the Ministry of Health and Family Welfare website, and 
individual program websites for their topic area of interest to check 
whether additional service use information is available.
Equity – provision and access
There are a number of sources of information across the country 
that provide information on equity, and a robust analyses of equity 
information to inform a given HTA should take into account multi-
ple data sources in order to provide a comprehensive assessment of 
this domain. Data may be extrapolated from large survey samples, 
such as the National Family Health Survey (NFHS), and the 
National Sample Survey Office (NSSO), and Health Management 
Information System portal, where data is available which links 
demographic information such as gender, geographic location, 
urban or rural dwelling, age, and socio-economic status to 
health behaviours and experiences. The Socio-economic and 
Caste Census was also conducted under the ministry of Rural 
Development in 2011, which provides additional comprehen-
sive information on these two social determinants of health. Data 
published by government insurance programs at both the national 
and state level, such as RSBY, may also be a useful source of 
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information regarding equity in the Indian context, where a number 
of published studies highlight inequitable access to social health 
insurance36,37. The recently published Global Burden of Disease 
India profile (201729), and Niti Aayog ‘Health States’ report25 
further highlight health inequity between states across the country 
and could also be used to inform equity analysis for the conduct 
of future HTA studies.
Future research – changing data landscape
India lies at a critical juncture, where political discourse regarding 
Universal Health Coverage has reinvigorated interest in improving 
the way in which healthcare is financed, purchased, provisioned, 
monitored, and governed. The institutionalisation of HTA for set-
ting evidence-based priorities, and the associated strengthening 
of a robust network of routinely collected and verifiable health 
data will be a vital lever for systemic reforms to transform India’s 
fragmented healthcare system. The World Health Organisa-
tion urges member states to develop and improve the collection 
of data on health intervention and technology assessment as part 
of their Health Intervention Technology Assessment Resolution 
(20144). If the government is committed to leveraging HTA as a 
tool for realising UHC, health information systems and the plat-
forms for collecting health data will need to be strengthened and 
adequately governed.
Strengthening data collection should begin at the clinical trial 
phase, where protocols can be put in place to ensure that cost, safety, 
efficacy, and socio-demographic information are collected from 
the earliest phases of technology development. In European coun-
tries where it is common process for technologies to go through a 
process of HTA before entering the market, such data is routinely 
collected by industry bodies in the development and piloting 
phases5. Improving the capture of data on health technologies in 
India, where the health technology industry is one of the largest 
and most powerful globally, would have important ramifications 
beyond India for the global health innovation market.
As a Nation leading global advances in technology, telecommuni-
cations systems, and mobile devices, there is significant opportu-
nity for India to leverage technological innovation to support health 
system strengthening. The rollout of Aadhar across the country, 
which provides each citizen with a unique and identifiable 
digital identity, gives rise to the possibility of linking health related 
information to individuals, and consolidating such data for 
macro-level surveillance and real-time quality improvement. 
The combination of the these unique digital identifiers and the 
ubiquitous access to technology further afford the opportunity 
to aggregate data, expertise, and experience from a variety of 
sources for health-focused problem-solving a learning health 
system. Working with large datasets enhances the ability to 
detect and monitor quality improvement, and can thus meet both 
clinical and business needs simultaneously. This is of particular 
importance in the Indian context, where the government relies on 
harnessing the power of the private sector through mutually 
beneficial public private partnerships to provide access to high 
quality publicly-funded healthcare.
It must be noted that much of the data described in this paper is 
derived from and government-sponsored information systems and 
census surveys, where specific objectives are present and thus the 
presence of bias cannot be discounted. Discrepancies between 
administrative data and independent household surveys from 
around the world suggest official statistics can systematically 
exaggerate development progress38, and Indian datasets are not 
immune to such criticisms39. As India transitions away from its 
reliance on large-scale international donor-funded studies towards 
locally-sourced datasets, additional measures for safeguarding 
data quality and protecting against perverse incentives and the 
political economy of inaccurate indicators will need to be put in 
place.
The improved accountability inherent in making health data more 
transparent can have important indirect consequences in measur-
ing and improving quality of service provision, and reducing low 
value care40. The ratification of the Indian Clinical Establishment 
Act in 2010 gives leverage to the government and private 
citizens alike to demand greater accountability of care across 
both the public and private sectors, and marks an important step 
forward towards more transparent health information provision. 
Improving the way health information is captured, reported, and 
utilised across the country benefits the entire population: the 
public are empowered to make informed choices regarding 
their own health, academics are afforded the opportunity to 
identify bottlenecks and potential levers for quality improve-
ment, and policy makers are equipped to make more robust, 
defendable, and evidence-based health policies for improving the 
health of the population.
Conclusions
This paper provides a novel and comprehensive framework to 
assess the availability and quality of local health data required 
for the conduct of Health Technology Assessment in India. While 
epidemiological information is routinely collected, other key 
data inputs such as costs, consumption, and quality of life are not 
readily available. This poses a significant bottleneck to the effi-
cient generation and deployment of HTA evidence into the health 
decision space in India. Overcoming these data gaps by strength-
ening the routine collection of comprehensive and verifiable 
health data will have important implications not only for embed-
ding HTA into the priority setting process, but for strengthening 
the Indian health system as a whole.
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